Seres Therapeutics Inc (NASDAQ:MCRB) has earned an average recommendation of “Hold” from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company.

A number of research analysts recently weighed in on the company. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating on shares of Seres Therapeutics in a report on Friday, February 22nd. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a report on Friday, January 4th. BidaskClub raised Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 14th. Finally, Cowen reaffirmed a “buy” rating on shares of Seres Therapeutics in a report on Friday, February 8th.

In other Seres Therapeutics news, EVP Thomas Desrosier sold 5,471 shares of the firm’s stock in a transaction that occurred on Monday, January 28th. The stock was sold at an average price of $5.75, for a total value of $31,458.25. Following the sale, the executive vice president now owns 21,525 shares of the company’s stock, valued at approximately $123,768.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric D. Shaff sold 4,378 shares of Seres Therapeutics stock in a transaction that occurred on Monday, January 28th. The stock was sold at an average price of $5.75, for a total value of $25,173.50. Following the sale, the insider now directly owns 17,220 shares in the company, valued at approximately $99,015. The disclosure for this sale can be found here. Company insiders own 37.10% of the company’s stock.

Several large investors have recently made changes to their positions in MCRB. Great West Life Assurance Co. Can acquired a new stake in shares of Seres Therapeutics during the 4th quarter worth approximately $30,000. Two Sigma Investments LP acquired a new stake in shares of Seres Therapeutics during the 4th quarter worth approximately $82,000. Rhumbline Advisers grew its holdings in shares of Seres Therapeutics by 48.8% during the 4th quarter. Rhumbline Advisers now owns 27,136 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 8,895 shares in the last quarter. Paloma Partners Management Co acquired a new stake in shares of Seres Therapeutics during the 3rd quarter worth approximately $147,000. Finally, Jefferies Group LLC grew its holdings in shares of Seres Therapeutics by 75.5% during the 3rd quarter. Jefferies Group LLC now owns 21,424 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 9,215 shares in the last quarter. 77.26% of the stock is currently owned by institutional investors.

Shares of MCRB stock traded up $0.03 during trading on Monday, reaching $6.82. The company had a trading volume of 145,000 shares, compared to its average volume of 330,699. Seres Therapeutics has a one year low of $4.42 and a one year high of $9.75. The company has a market capitalization of $277.91 million, a price-to-earnings ratio of -2.81 and a beta of 1.85.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.15. Seres Therapeutics had a negative return on equity of 1,584.13% and a negative net margin of 350.03%. The business had revenue of $10.63 million for the quarter, compared to the consensus estimate of $3.78 million. Sell-side analysts predict that Seres Therapeutics will post -1.79 earnings per share for the current fiscal year.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Featured Story: How much can an individual set aside as a catch-up contribution?

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.